21st Century Cures Rolls Thru House, Price Poised to Gut Obamacare, and Bluebird Soars

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Vertex’s Next Big Thing, Regeneron’s Cell Therapy Play, & Takeda Bets on Protagonist
Sanofi Shells Out for Inhibrx, CG’s Breakout IPO, & a Cure for a Rare Deafness
GSK Buys TSLP Antibody, J&J’s ADC Play, & Merck Adds Harpoon T-Cell Engagers
Karuna and RayzeBio Acquired, TCGX’s $1B Crossover Bet, & Cytokinetics’ Breakout